SG11201404921QA - Method for treating gynecological diseases - Google Patents

Method for treating gynecological diseases

Info

Publication number
SG11201404921QA
SG11201404921QA SG11201404921QA SG11201404921QA SG11201404921QA SG 11201404921Q A SG11201404921Q A SG 11201404921QA SG 11201404921Q A SG11201404921Q A SG 11201404921QA SG 11201404921Q A SG11201404921Q A SG 11201404921QA SG 11201404921Q A SG11201404921Q A SG 11201404921QA
Authority
SG
Singapore
Prior art keywords
gynecological diseases
treating gynecological
treating
diseases
gynecological
Prior art date
Application number
SG11201404921QA
Inventor
Jean-Pierre Gotteland
Valérie Boujac
Ernest Loumaye
Original Assignee
Preglem Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Preglem Sa filed Critical Preglem Sa
Publication of SG11201404921QA publication Critical patent/SG11201404921QA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
SG11201404921QA 2012-03-23 2013-03-22 Method for treating gynecological diseases SG11201404921QA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261614785P 2012-03-23 2012-03-23
EP12160956.4A EP2641602A1 (en) 2012-03-23 2012-03-23 Method for treating gynecological diseases
PCT/IB2013/052274 WO2013140372A1 (en) 2012-03-23 2013-03-22 Method for treating gynecological diseases

Publications (1)

Publication Number Publication Date
SG11201404921QA true SG11201404921QA (en) 2014-10-30

Family

ID=45976689

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201404921QA SG11201404921QA (en) 2012-03-23 2013-03-22 Method for treating gynecological diseases

Country Status (18)

Country Link
US (1) US10441534B2 (en)
EP (3) EP2641602A1 (en)
JP (2) JP2015514700A (en)
KR (1) KR20140138824A (en)
CN (1) CN104203246A (en)
AU (1) AU2013236960B2 (en)
CA (1) CA2864073A1 (en)
CO (1) CO7111317A2 (en)
EA (1) EA031488B1 (en)
GE (1) GEP201706696B (en)
HK (1) HK1199827A1 (en)
MX (1) MX369520B (en)
MY (1) MY172530A (en)
NZ (1) NZ630011A (en)
SG (1) SG11201404921QA (en)
TW (2) TW201400121A (en)
WO (1) WO2013140372A1 (en)
ZA (1) ZA201407575B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3009525A1 (en) 2015-12-23 2017-06-29 Oric Pharmaceuticals, Inc. Inhibitors of glucocorticoid receptor
WO2017112904A1 (en) 2015-12-23 2017-06-29 Oric Pharmaceuticals, Inc. Inhibitors of glucocorticoid receptor
WO2017112902A1 (en) 2015-12-23 2017-06-29 Oric Pharmaceuticals, Inc. Inhibitors of glucocorticoid receptor
WO2017165707A1 (en) * 2016-03-24 2017-09-28 Juniper Pharmaceuticals, Inc. Vaginal administration of agents for treating and preventing pain associated with gynecological medical procedures
NZ753142A (en) 2016-10-07 2020-08-28 Oric Pharmaceuticals Inc Inhibitors of glucocorticoid receptor

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3545439A (en) 1968-01-04 1970-12-08 Upjohn Co Medicated devices and methods
US3920805A (en) 1971-12-09 1975-11-18 Upjohn Co Pharmaceutical devices and method
US4155991A (en) 1974-10-18 1979-05-22 Schering Aktiengesellschaft Vaginal ring
IL48277A (en) 1974-10-18 1978-03-10 Schering Ag Vaginal ring
US3995633A (en) 1975-12-02 1976-12-07 The Procter & Gamble Company Vaginal Medicament dispensing device
US3995634A (en) 1975-12-02 1976-12-07 The Procter & Gamble Company Vaginal cavity dispensing means and method
US3991760A (en) 1975-12-02 1976-11-16 The Procter & Gamble Company Vaginal medicament dispensing means
US4286587A (en) 1978-10-11 1981-09-01 Alza Corporation Vaginal drug delivery system made from polymer
US4292965A (en) 1978-12-29 1981-10-06 The Population Council, Inc. Intravaginal ring
US4250611A (en) 1979-04-19 1981-02-17 Alza Corporation Process for making drug delivery device with reservoir
US4596576A (en) 1984-10-12 1986-06-24 Akzo N.V. Release system for two or more active substances
NL8500470A (en) 1985-02-19 1986-09-16 Achel Homesteel Pvba Expandable intra:vaginal ring without diaphragm - opt. has cavity contg. spermicide or medicament
US4954490A (en) 1988-06-23 1990-09-04 Research Triangle Institute 11 β-substituted progesterone analogs
FI95768C (en) 1993-06-17 1996-03-25 Leiras Oy Intravaginal dosing system
US5929262A (en) 1995-03-30 1999-07-27 The United States Of America As Represented By The Department Of Health And Human Services Method for preparing 17α-acetoxy-11β-(4-N, N-dimethylaminophyl)-19-Norpregna-4,9-diene-3, 20-dione, intermediates useful in the method, and methods for the preparation of such intermediates
US5972372A (en) 1996-07-31 1999-10-26 The Population Council, Inc. Intravaginal rings with insertable drug-containing core
ES2212912B1 (en) 2003-01-22 2005-10-01 Crystal Pharma, S.A. PROCEDURE FOR OBTAINING 17ALFA-ACETOXI-11BETA- (4-N, N-DIMETHYLAMINEPHENYL) -19-NORPREGNA-4,9-DIEN-3,20-DIONA.
CA2516319C (en) 2003-02-28 2012-09-18 The Government Of The United States Of America, As Represented By The Se Cretary, Department Of Health And Human Services Method for preparing 17.alpha.-acetoxy-11.beta.-(4-n,n-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione, intermediates thereof, and methods for the preparation of such intermediates
ES2360806T3 (en) 2004-07-09 2011-06-09 The Population Council, Inc. PROLONGED RELEASE COMPOSITIONS CONTAINING PROGESTERONE RECEIVER MODULATORS.
EP2148681B1 (en) * 2007-04-20 2016-03-16 PregLem S.A. Selective progesterone modulators in the treatment of uterine bleeding
US8299050B2 (en) * 2008-01-29 2012-10-30 Laboratoire Hra-Pharma Method for treating uterine fibroids
ES2645630T3 (en) * 2008-02-04 2017-12-07 Ferring B.V. Monolithic intravaginal rings comprising progesterone and manufacturing methods and uses thereof

Also Published As

Publication number Publication date
MY172530A (en) 2019-11-29
MX369520B (en) 2019-11-11
EP2641602A1 (en) 2013-09-25
KR20140138824A (en) 2014-12-04
AU2013236960A1 (en) 2014-09-25
NZ630011A (en) 2016-12-23
EP2827873A1 (en) 2015-01-28
JP2015514700A (en) 2015-05-21
US10441534B2 (en) 2019-10-15
EA031488B1 (en) 2019-01-31
GEP201706696B (en) 2017-07-10
CO7111317A2 (en) 2014-11-10
MX2014011487A (en) 2015-01-12
US20150038476A1 (en) 2015-02-05
CN104203246A (en) 2014-12-10
AU2013236960B2 (en) 2017-11-23
ZA201407575B (en) 2015-12-23
WO2013140372A1 (en) 2013-09-26
JP2018109025A (en) 2018-07-12
CA2864073A1 (en) 2013-09-26
HK1199827A1 (en) 2015-07-24
EA201491614A1 (en) 2015-01-30
TW201400121A (en) 2014-01-01
TW201832767A (en) 2018-09-16
EP3363500A1 (en) 2018-08-22

Similar Documents

Publication Publication Date Title
HK1212972A1 (en) Pyrrolo- and pyrazolo-triazolodiazepines as bet-protein inhibitors for treating hyperproliferative diseases bet---
PL3783118T3 (en) Method for manufacturing press-hardened parts
EP2611765A4 (en) Methods for treating neurodegenerative diseases
DK3292875T3 (en) Compositions and methods for treating diseases
ZA201208219B (en) Method for treating wasterwater
HK1215173A1 (en) Methods of treating s. aureus-associated diseases
HK1204452A1 (en) Treatment for bone diseases
HK1203370A1 (en) Method for treatment of labor arrest
HK1216504A1 (en) Method for treatment of diseases
HK1199827A1 (en) Method for treating gynecological diseases
EP2816126A4 (en) Heat treatment method
EP2854784A4 (en) Method for treating skin inflammatory diseases
EP2849778A4 (en) Method for treating inflammation
PL2809760T3 (en) Process for reducing malodours
IL234796B (en) Compounds for the treatment of ischemia-reperfusion-related diseases
EP2882432A4 (en) Method for the treatment of acne
GB201121950D0 (en) Treatment process
HK1209040A1 (en) Methods for treating vestibulotoxicity
ZA201407215B (en) Method for emulsion treatment
GB201105523D0 (en) Treatment method
PL2730177T3 (en) Method for treating eggs
EP2813798A4 (en) Blast treatment method
EP2854774A4 (en) Methods for treating insomnia
GB201205449D0 (en) Treatment process
GB201217173D0 (en) Therapeutic method